Evidence map›Paper›PMID 36513904›Full record

ArticleFamilial cancer2023

Two unique BAP1 pathogenic variants identified in the same family by panel cascade testing.

Lindsey Byrne, Cana Ingalls, Aliya Ansari, Cassie Porteus, Talia R Donenberg, Daniel A Sussman, Colleen M Cebulla, Mohamed H Abdel-Rahman

Open access · greenAbstract readCase Reports
In one paragraph

Article in Familial cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lindsey ByrneDivision of Human Genetics and James Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Lindsey.byrne@osumc.edu.
Cana IngallsDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Aliya AnsariDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Cassie PorteusDivision of Human Genetics and James Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Talia R DonenbergDivision of Clinical and Translational Genetics, University of Miami Miller School of Medicine, Miami, FL, USA.
Daniel A SussmanDivision of Gastroentrology, Department of Medicine, University of Miami, Miami, USA.
Colleen M CebullaDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Mohamed H Abdel-RahmanDivision of Human Genetics and James Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. mohamed.abdel-rahman@osumc.edu.ORCID http://orcid.org/0000-0002-9493-7894
The Ohio State University Wexner Medical Center · USUniversity of Miami · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The Ohio State University Center for Clinical and Translational Science (UL1)UL1TR000090 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2012 to 2013
$7.9M
Spectrum of clinical phenotype of the BAP1-tumor predisposition syndrome (BAP1-TPDS)R01CA255323 · NCI · OHIO STATE UNIVERSITY · PI ABDEL-RAHMAN, MOHAMED H. · 2021 to 2025
$2.9M
Hereditary cancer predisposition syndromes and uveal melanomaR21CA191943 · NCI · OHIO STATE UNIVERSITY · PI ABDEL-RAHMAN, MOHAMED H. · 2015 to 2016
$368k
NCATS NIH HHS UL1 TR000090NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA255323NCI NIH HHS R21 CA191943NCI NIH HHS R21CA191943
6 · The paper itself

Abstract

Germline pathogenic variants in the tumor suppressor gene BAP1 are associated with the hereditary tumor predisposition syndrome with susceptibility to uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and other cancers. Germline BAP1 pathogenic variants are rare in the non-cancer general population with an estimated carrier frequency of 1:19,898 but more common in cancer patients with a carrier frequency of 1:1299. In the following we present the first report of a family with two unique BAP1 pathogenic variants. Retrospective case report of a family with two unique pathogenic variants in BAP1. A male (proband) was referred to our ocular oncology clinic for second opinion for his multiple independent uveal melanomas at ages 65, 68 and 71. Given his personal history of squamous cell carcinoma at age 61, renal cell carcinoma at age 63, and family history of atypical meningioma, basal cell carcinoma, pancreatic and prostate cancers he was assessed for germline pathogenic variants in BAP1 through our ongoing research study. Sanger sequencing identified the American founder pathogenic variant, c.1717delC, pL573Wfs*3, that was confirmed in a clinical laboratory. Both the proband's brother and nephew tested negative for the familial variant through single site cascade genetic testing. However, based on the personal history of multiple basal cell carcinoma in the nephew and family history of pancreatic and laryngeal cancers (both not known to be associated with BAP1-TPDS), a large cancer panel testing was recommended for the nephew. His panel testing revealed a different BAP1 pathogenic variant, c.605G>A, p. Trp202*. This variant was not detected in the proband or the proband's brother. Based on the frequency of germline BAP1 variants in the cancer population, the chance of occurrence of two different BAP1 variants in a family with cancer history is 5.9 × 10

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMelanomaNeoplastic Syndromes, HereditarySkin NeoplasmsGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleMiddle AgedRetrospective StudiesTumor Suppressor ProteinsUbiquitin ThiolesteraseUveal MelanomaUveal NeoplasmsBAP1 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1Case reportFamilial cancerPanel cascade genetic testing

Identifiers

PMID36513904
PMCPMC10264546
OpenAlexW4311308286

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.